104 results
6-K
EX-4.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding … other cases, the fair market value of an Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority
6-K
EX-4.2
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding … other cases, the fair market value of an Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority
6-K
EX-4.4
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
price per Ordinary Share so reported, or (d) in all other cases, the fair market value of an Ordinary Share as determined by an independent appraiser … of an Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities
6-K
EX-4.5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
price per Ordinary Share so reported, or (d) in all other cases, the fair market value of an Ordinary Share as determined by an independent appraiser … of an Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities
6-K
EX-1.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.
(dd) Accountants. The Company’s independent … Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation
6-K
EX-4.3
m8ofi9b
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
424B5
aeol962xmd
29 May 24
Prospectus supplement for primary offering
4:15pm
6-K
EX-99.1
ydzbqfy3am6kn3gt
22 Apr 24
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
abqp52
16 Apr 24
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
8gzb1v0g9so
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
6-K
EX-99.2
jjidhnmxqs 3i
29 Mar 24
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
3jz4 bqvq
29 Mar 24
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
8qcujh
17 Jan 24
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
bh9dsq o3l5rbc
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
6-K
EX-99.2
apgtct7
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
6-K
EX-99.1
anxzd3spd9s uqf4
17 Apr 23
Enlivex Appoints Andrew Singer to its Board of Directors
8:03am
6-K
c0a5veflw8k4d4k60k
17 Apr 23
Enlivex Appoints Andrew Singer to its Board of Directors
8:03am